Nature CommunicationsBioinformaticsPeer-reviewed journal article
First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa
Gemma TuróniD, Jason HlozekiD, John G. WoodlandiD, Ankur KumariD, Kelly ChibaleiD, Miquel Duran‐FrigolaiD
Abstract
We present ZairaChem, an artificial intelligence (AI)- and machine learning (ML)-based tool to train small-molecule activity prediction models. ZairaChem is fully automated, requires low computational resources and works across a broad spectrum of datasets, ranging from whole-cell growth inhibition assays to drug metabolism properties. The tool has been implemented end-to-end at the Holistic Drug Discovery and Development (H3D) Centre, the leading integrated drug discovery unit in Africa, at which no prior AI/ML capabilities were available. We have exploited in-house data collected from over a decade of drug discovery research in malaria and tuberculosis and built models to predict the outcomes of 15 key checkpoint assays. We subsequently deployed these models as a virtual screening cascade at an organisational scale to increase the hit rate of current experimental assays. We show how computational profiling of compounds, prior to synthesis and experimental testing, can increase the rate of progression by up to 40%. Moreover, we demonstrate that the approach can be applied to prioritise small molecules within a chemical series and to assess the likelihood of success of novel chemotypes, promoting efficient usage of limited experimental resources. This project is part of a first-of-its-kind collaboration between the H3D Centre, a research centre operating in a low-resource setting, and the Ersilia Open Source Initiative, a young tech non-profit devoted to building data science capacity in the Global South.
- Citations
- 95
- FWCI
- 13.55
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Establishing the foundations for a data-centric AI approach for virtual drug screening through a systematic assessment of the properties of chemical data
Allen Chong, Ser-Xian Phua, … Wilson Wen Bin Goh·bioRxiv·Mar 28, 2024
- Machine Learning-Based Drug Response Prediction Identifies Novel Therapeutic Candidates for Colorectal Cancer Cell Line KM-12
Cyrine Chanchabi, Conception Paul, … Michael Hahne·bioRxiv·Feb 24, 2025
- ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery
Tyler J. Umansky, Virgil A. Woods, … Daniel J. Haders·bioRxiv·Mar 22, 2024
- Accelerating Drug Discovery with HyperLab: An Easy-to-Use AI-Driven Platform
HyperLab team, Jaechang Lim·bioRxiv·Aug 31, 2025
- vScreenML v2.0: Improved Machine Learning Classification for Reducing False Positives in Structure-Based Virtual Screening
Grigorii V. Andrianov, Emeline Haroldsen, John Karanicolas·International Journal of Molecular SciencesPeer-reviewed·Nov 18, 2024
- Do Larger Models Really Win in Drug Discovery?A Benchmark Assessment of Model Scaling in AI-Driven Molecular Property and Activity Prediction
Jinjiang Guo, Sheng Ding·bioRxiv·Jun 8, 2026